The estimated Net Worth of Michael Cloonan is at least $5.14 Milion dollars as of 22 May 2019. Mr. Cloonan owns over 25,000 units of Sage Therapeutics Inc stock worth over $190,703 and over the last 8 years he sold SAGE stock worth over $0. In addition, he makes $4,952,920 as Chief Operating Officer at Sage Therapeutics Inc.
Sign up
Mr. Cloonan SAGE stock SEC Form 4 insiders trading
Michael has made over 1 trades of the Sage Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of SAGE stock worth $1,835,750 on 22 May 2019.
The largest trade he's ever made was exercising 25,000 units of Sage Therapeutics Inc stock on 22 May 2019 worth over $1,835,750. On average, Michael trades about 2,500 units every 0 days since 2017. As of 22 May 2019 he still owns at least 25,461 units of Sage Therapeutics Inc stock.
You can see the complete history of Mr. Cloonan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Cloonan biography
Michael Cloonan serves as Chief Operating Officer of the Company. Prior to joining us, Mr. Cloonan worked in various leadership positions at Biogen, Inc. from 2003 to 2017, including Senior Vice President, US Commercial from 2015 to 2017, Senior Vice President, Global Commercial Strategy from 2014 to 2015, Managing Director, Australia and New Zealand affiliate from 2011 to 2014, Vice President, Business Planning from 2010 to 2011, Senior Director, Patient Services US Commercial from 2008 to 2010, and Director, Business Planning from 2003 to 2008. Mr. Cloonan received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and his B.A. in economics and accounting from the College of the Holy Cross.
What is the salary of Michael Cloonan?
As the Chief Operating Officer of Sage Therapeutics Inc, the total compensation of Michael Cloonan at Sage Therapeutics Inc is $4,952,920. There are 1 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
How old is Michael Cloonan?
Michael Cloonan is 49, he's been the Chief Operating Officer of Sage Therapeutics Inc since 2020. There are 16 older and no younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
What's Michael Cloonan's mailing address?
Michael's mailing address filed with the SEC is C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE, MA, 02145.
Insiders trading at Sage Therapeutics Inc
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen a Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
What does Sage Therapeutics Inc do?
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
What does Sage Therapeutics Inc's logo look like?
Complete history of Mr. Cloonan stock trades at Bluebird bio Inc a Sage Therapeutics Inc
Sage Therapeutics Inc executives and stock owners
Sage Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Jonas,
President, Chief Executive Officer and Director -
Michael Cloonan,
Chief Operating Officer -
Stephen Kanes,
Chief Medical Officer -
Anne Cook,
Senior Vice President, General Counsel, Secretary -
Kimi Iguchi,
Chief Financial Officer, Treasurer -
Albert Robichaud,
Chief Scientific Officer -
Elizabeth Barrett,
Independent Director -
George Golumbeski,
Independent Director -
Dr. Jeffrey M. Jonas,
Chief Innovation Officer, Chair of the Science & Technology Forum and Director -
Kevin Starr,
Independent Chairman of the Board -
Michael Cola,
Independent Director -
James Frates,
Independent Director -
Steven Paul,
Independent Director -
Geno Germano,
Independent Director -
Asha Nayak,
Independent Director -
Anne Marie Cook,
Sr. VP, Gen. Counsel & Sec. -
Dr. Albert J. Robichaud Ph.D.,
Chief Scientific Officer -
Kimi E. Iguchi,
CFO & Treasurer -
Barry E. Greene,
Pres, CEO & Director -
Barry Greene,
Director -
Dr. Jim Doherty Ph.D.,
Chief Devel. Officer -
Dr. Amy Schacterle Ph.D.,
Sr. VP of R&D Strategy and Bus. Management -
Erin E. Lanciani,
Chief People & Experience Officer -
Helen Rubinstein,
Investor Relations Officer -
Matt Lasmanis,
Chief Technology & Innovation Officer -
Rock Ventures Ii, L.P.Third...,
-
Howard H Pien,
-
Thomas Anderson,
See Remarks -
Robert Nelsen,
Director -
Venture Fund Vii Lparch Ven...,
-
Rock Ventures Ii, L.P.Third...,
-
Laura Gault,
Chief Medical Officer -
Jessica Federer,
-
Christopher Benecchi,
Chief Business Officer